CalciMedica Posts $5M Q1 Net Profit, Reversing Loss; Awaits Key FDA Feedback
Summary
CalciMedica reported a Q1 net income of $5.0 million, reversing a year-ago loss. This significant net profit for the micro-cap company was primarily driven by fair value adjustments to financial instruments and lower operating expenses, including reduced R&D and personnel costs, rather than core operational profitability, as the company still posted an operating loss of $5.61 million. This financial update follows the company's announcement of strong Phase 2b clinical trial results for Auxora earlier today. The company also expects crucial FDA feedback on its Auxora pivotal program in acute pancreatitis during Q2 2026, which will be a major catalyst. Traders will weigh the non-operational profit against the positive clinical news and upcoming regulatory milestone.
At the time of this announcement, CALC was trading at $0.59 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $9.3M. The 52-week trading range was $0.46 to $7.20. This news item was assessed with neutral market sentiment and an importance score of 8 out of 10. Source: Reuters.